The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
At the 2026 ASCO Annual Meeting, Marc Hoffman, MD, of the University of Kansas Cancer Center, discusses results from the ongoing GOLSEEK-1 trial of golcadomide.
The anito-cel analysis covered 104 patients enrolled and leukapheresed in iMMagine-3 or GEM-AnitoFirst from September 2024 to October 2025. Anito-cel lots were successfully manufactured for all patients, and 101 out of 102 lots were manufactured successfully on the first pass.
Dr. Usmani and Mina discuss the pivotal phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy for patients with relapsed/refractory multiple myeloma who were previously exposed to lenalidomide and anti-CD38 antibodies.
There have been concerns about whether vaccines work well in patients who have received CAR-T therapy and whether vaccination would increase the risk of cytokine release syndrome or other immune-related toxicities in this vulnerable population.
Hans Lee, MD, director of Myeloma Research at the Sarah Cannon Research Institute, discusses an early phase 1/2 clinical trial evaluating the investigational therapy mRNA-2808
At age 28, he was a senior registrar in clinical and laboratory haematology at Addenbrooke’s Hospital in Cambridge. After earning his MRCPath at age 31, he was appointed a consultant in clinical haematology at University College Hospital (UCH) in London.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
